• Michael R. Swenson


The immune system is that collection of tissues and organs devoted to the defense of self, an action usually directed against infectious pathogens—parasites, fungi, viruses, and bacteria. Antigens are the distinguishing characteristics of pathogens, usually foreign molecules, used by the immune system as a target for identification of an invader and for direction of attack.


Multiple Sclerosis Amyotrophic Lateral Sclerosis Plasma Exchange Optic Neuritis Inclusion Body Myositis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Genkins G, Kornfeld P, Papatestas AE, et al.: Clinical experience in more than 2,000 patients with myasthenia gravis. Ann NY Acad Sci 1987, 505:500–513.PubMedCrossRefGoogle Scholar
  2. 2.
    Dalakas MC: Polymyositis, dermatomyositis, and inclusion body myositis. N Engl J Med 1991, 325 (21): 1487–1498.PubMedCrossRefGoogle Scholar
  3. 3.
    Sibley WA, Bamford CR, Clark K: Triggering Factors in Multiple Sclerosis. In Diagnosis of Multiple Sclerosis. Edited by Poser CM, Paty DW, Scheinberg L. New York: Thieme-Stratton; 1984:14.Google Scholar
  4. 4.
    Constantinescu CS, Cohen JA: Regulatory-cytokine therapy for autoimmune diseases: Implications for multiple sclerosis. Multiple Sclerosis: Clinical Issues 1994, 1 (3): 6–9.Google Scholar
  5. 5.
    Glaser JS: Topical Diagnosis: Prechiasmal Visual Pathways. In Neuroophthalmology, edn 2. Edited by Glaser JS. Philadelphia: JB Lippincott; 1990: 123–128.Google Scholar
  6. 6.
    Francis DA, Compston DA, Batchelor JR, et al.: A reassessment of the risk of MS developing in patients with optic neuritis after extended follòw-up. J Neurol Neurosurg Psychiatry 1987, 50(6):758–765.Google Scholar
  7. 7.
    Leys D, Petit H, Block AM, et al.: Neuromyelitis optica (Devic’s disease): four cases. Rev Neurol (Paris) 1987, 143:722.Google Scholar
  8. 8.
    Poser CM, Paty DW, Scheinberg L, et al.: New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983, 13:227–231.Google Scholar
  9. 9.
    Ohman S, Ernerudh J, Forsberg P, et al.: Comparison of seven formulae and isoelectric focusing for determining of intrathecally producing IgG in neurological diseases. Ann Clin Biochem 1992, 29:405–410.Google Scholar
  10. 10.
    Stendahl Brodin L, Link H: Optic neuritis: oligoclonal bands increase the risk of multiple sclerosis. Acta Neurol Scand 1983, 67: 301–304.PubMedCrossRefGoogle Scholar
  11. 11.
    Yock DH: White Matter Disorders. In Magnetic Resonance Imaging of CNS Disease, Chap. 7. St. Louis: Mosby-Year Book; 1995.Google Scholar
  12. 12.
    Thorp JW, Miller DH: MRI: its application and impact. Internat MS J 1994, 1 (1): 7–15.Google Scholar
  13. 13.
    Comi G, Filippi M, Martinelli V, et al.: Brain stem magnetic resonance imaging and evoked potential studies of symptomatic multiple sclerosis patients. Eur Neurol 1993, 33:232–237.Google Scholar
  14. 14.
    McDonald WI, Miller DH: Spinal cord MRI using multi-array coils and fast spin echo. II. Findings in multiple sclerosis. Neurology 1993, 43: 2632–2637.PubMedCrossRefGoogle Scholar
  15. 15.
    Kastrukoff LF, Oger JJ, Hashimoto SA, et al.: Systemic lymphoblastoid interferon therapy in chronic progressive multiple sclerosis. I. Clinical and MRI evaluation. Neurology 1990, 40:479–486.Google Scholar
  16. 16.
    Koopmans RA, Li DKB, Zhao GJ, et al.: MRI assessment of cyclosporine therapy of MS in a multi-center trial. Neurology 1992, 42(suppl 3):210.Google Scholar
  17. 17.
    Thompson AJ, Miller D, Youl B, et al.: Serial gadolinium-enhanced MRI in relapsing/remitting multiple sclerosis of varying disease duration. Neurology 1992, 42:60–63.Google Scholar
  18. 18.
    Offenbacher H, Fazekas F, Schmidt R, et al.: Assessment of MRI criteria for a diagnosis of MS. Neurology 1993, 43:905–909.Google Scholar
  19. 19.
    Filippi M, Martinelli V, Sirabian G, et al.: Brain magnetic resonance imaging correlates of cognitive impairment in multiple sclerosis. J Neurol Sci 1993, 115(suppl):566–873.Google Scholar
  20. 20.
    IFNB Multiple Sclerosis Study Group: Interferon 3-lb is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo controlled trial. Neurology 1993, 43 (4): 655–661.Google Scholar
  21. 21.
    Paty DW, Li DKB, UBC MS/MRI Study Group, IFNB Multiple Sclerosis Study Group: Interferon r3-lb is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo controlled trial. Neurology 1993, 43 (4): 662–667.Google Scholar
  22. 22.
    Wolinsky JS: Copolymer 1: A most reasonable alternative therapy for early relapsing-remitting multiple sclerosis with mild disability. Neurology 1995, 45 (7): 1245–1247.PubMedCrossRefGoogle Scholar
  23. 23.
    Beck RW, Cleary PA, Anderson MM, et al.: A randomized controlled trial of corticosteroids in the treatment of acute optic neuritis. N Engl J Med 1992, 326(9):581–588.Google Scholar
  24. 24.
    Weiner HL, Mackin GA, Orav EJ, et al.: Intermittent cyclophosphamide pulse therapy in progressive multiple sclerosis: final report of the Northeast Cooperative Multiple Sclerosis Treatment Group. Neurology 1993, 43(5):910–918.Google Scholar
  25. 25.
    Canadian Cooperative Multiple Sclerosis Study Group: The Canadian Cooperative Trial of cyclophosphamide and plasma exchange in progressive multiple sclerosis. Lancet 1991, 337: 441–446.Google Scholar
  26. 26.
    Goodkin DE, Rudick RA, Medendorp SV, et al.: Low dose oral weekly methotrexate (MTX) significantly reduces the frequency of progression of impairment in patients with chronic progressive multiple sclerosis (CPMS). Neurology 1994, 44:A357.Google Scholar
  27. 27.
    Sipe JC, Romine JS, Koziol JA, et al.: Cladribine in treatment of chronic progressive multiple sclerosis. Lancet 1994, 344(8914):9–13.Google Scholar
  28. 28.
    Milligan NM, Miller DH, Compston DAS: A placebo-controlled trial of isoprinosine in patients with multiple sclerosis. J Neurol Neurosurg Psychiatry 1994, 57 (2): 164–168.PubMedCrossRefGoogle Scholar
  29. 29.
    Wiles CM, Omar L, Swan AV, et al.: Total lymphoid irradiation in multiple sclerosis. J Neurol Neurosurg Psychiatry 1994, 57(2):154–163.Google Scholar
  30. 30.
    Miller A, Lider O, Roberts AB, et al.: Suppressor T cells generated by oral tolerization to myelin basic proteins suppress both in vitro and in vivo immune responses by the release of transforming growth factor after antigen specific triggering. Proc Nat Acad Sci 1992, 89:421.Google Scholar
  31. 31.
    Weiner HL, Mackin GE, Matsui M, et al.: Double-blind pilot trial of oral tolerization with myelin antigens in multiple sclerosis. Science 1993, 259(5099):1321–1324.Google Scholar
  32. 32.
    Achiron A, Pras E, Gilad R, et al.: Open controlled therapeutic trial of intravenous immunoglobulin in relapsing-remitting multiple sclerosis. Arch Neurol 1992,49(12):1233–1236.Google Scholar
  33. 33.
    Rodriguez M, Karnes WE, Bartleson JD, et al.: Plasmapheresis in acute episodes of fulminant CNS inflammatory demyelination. Neurology 1993, 43(6):1100–1104.Google Scholar
  34. 34.
    IFNB Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group. Interferon 13-lb in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. Neurology 1995, 45: 1277–1285.Google Scholar
  35. 35.
    Johnson KP, Brooks BR, Cohen JA, et al.,and the Copolymer 1 Multiple Sclerosis Study Group: Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind, placebo controlled trial. Neurology 1995, 45:1268–1276.Google Scholar
  36. 36.
    Noseworthy JH, Hopkins MB, Vandervoort MK, et al.: An open trial evaluation of mitoxantrone in the treatment of progressive MS. Neurology 1993, 43(7):1401–1406.Google Scholar
  37. 37.
    Graus F, Dalmau JO: Management of paraneoplastic neurological syndromes. In Neurological Complications of Cancer. Edited by Wiley RO. New York: Marcel Dekker; 1995: 167–198.Google Scholar
  38. 38.
    Posner JB: Paraneoplastic syndromes. In Neurological Complications of Cancer. Edited by Posner JB. Philadelphia: FA Davis; 1995: 353–384.Google Scholar
  39. 39.
    Jacobson DM, Thirkill CL, Tipping SJ: A clinical triad to diagnose paraneoplastic retinopathy. Ann Neurol 1990, 28 (2): 162–167.PubMedCrossRefGoogle Scholar
  40. 40.
    Dropcho EJ: Autoimmune central nervous system paraneoplastic disorders: Mechanisms, diagnosis and therapeutic options. Ann Neurol 1995, 37 (suppl 1): 5102 - S113.CrossRefGoogle Scholar
  41. 41.
    Greenlees J, Brashear HR: Remote effects of carcinoma. In Current Therapy in Neurologic Disease. Edited by Johnson RT, Griffin JW. St. Louis: Mosby-Year Book; 1995: 167–198.Google Scholar
  42. 42.
    Brashear HR: Antibody testing: Finding the inside track to early diagnosis of CNS paraneoplastic syndromes. Adv Neuroimmunol 1995, 2 (3): 3–11.Google Scholar
  43. 43.
    Meinck HM, Ricker K, Hulser PJ, et al.: Stiff-man’s syndrome: neurophysiological findings in 8 patients. J Neurol 1995, 242(3):134–142.Google Scholar
  44. 44.
    Meinck H, Ricker K, Hulser PJ, et al.: Stiff-man’s syndrome: clinical and laboratory findings in 8 patients. J Neurol 1994, 241(3):157–166.Google Scholar
  45. 45.
    Folli F, Solimena M, Cofiell R, et al.: Autoantibodies to a 128-kd synaptic protein in 3 women with stiff-man syndrome and breast cancer. N Engl J Med 1993, 328(8):546–551.Google Scholar
  46. 46.
    Smith RG, Engelhardt JI, Tajti J, et al.: Experimental immune-mediated motor neuron diseases: models for human ALS. Brain Res Bull 1993, 30:373–380.Google Scholar
  47. 47.
    Rogers SW, Andrews PI, Gahring LC, et al.: Autoantibodies to glutamate receptor 3 in Rasmussen’s encephalitis. Science 1994, 265:648–651.Google Scholar
  48. 48.
    Parry GJ: Inflammatory demyelinating polyneuropathies: new perspectives in treatment. Adv Neuroimmunol 1994, 1 (1): 9–15.Google Scholar
  49. 49.
    Dyck PJ, Daube J, O’Brien P, et al.: Plasma exchange in chronic inflammatory demyelinating polyradiculoneuropathy. N Engl J Med 1986, 314:461–465.Google Scholar
  50. 50.
    Dyck PJ, Litchy WJ, Kratz KM, et al.: A plasma exchange versus immune globulin infusion trial in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neural 1994, 36(6):838–845.Google Scholar
  51. 51.
    Krendel DA, Successful treatment of neuropathies in patients with diabetes mellitus. Arch Neurol 1995, 52: 1053–1061.PubMedCrossRefGoogle Scholar
  52. 52.
    Kissel JT, Mendel JR: Vasculitic neuropathy. Neural Clin 1992, 10: 761–781.Google Scholar
  53. 53.
    Olney RK: Neuropathies in connective tissue disease. Muscle Nerve 1992, 15: 531–542.PubMedCrossRefGoogle Scholar
  54. 54.
    van der Meche FGA, Schmitz PIM, and the Dutch Guillain-Barré Study Group: A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barré syndrome. N Engl J Med 1992, 326 (17): 1123–1129.Google Scholar
  55. 55.
    Hayes MT: Analyzing new strategies to diagnose and treat autoimmune neuropathies. Adv Neuroimmunol 1995, 2 (2): 10–17.Google Scholar
  56. 56.
    Parry G, Swenson MR: When is antibody testing useful and what therapy is effective in immune-mediated neuropathies? Adv Neuroimmunol 1995, 2 (2): 18–22.Google Scholar
  57. 57.
    Odabasi Z, Joy JL, Claussen GC, et al.: Isaacs’ syndrome associated with chronic inflammatory demyelinating polyneuropathy. Muscle Nerve 1996, 19:210–215.Google Scholar
  58. 58.
    Newsom-Davis J, Mills KR: Immunological associations of acquired neuromyotonia (Isaacs’ syndrome): report of five cases and literature review. Brain 1993, 116 (part III): 453–469.PubMedCrossRefGoogle Scholar
  59. 59.
    Sinha S, Newsom-Davis J, Mills K, et al.: Autoimmune aetiology for acquired neuromyotonia (Isaacs’ syndrome). Lancet 1991, 338(8759):75–77.Google Scholar
  60. 60.
    Quarles RH, Colman DR, Salzer JL, et al.: Myelin associated glycoprotein: structure-function relationships and involvement in neurological diseases. In Myelin: Biology and Chemistry. Edited by Martenson RE. Boca Raton, FL: CRC Press; 1992:413–448.Google Scholar
  61. 61.
    Quarles RH: Antibody mediated neuropathies exploring the pathogenic mechanisms. Adv Neuroimmunol 1995, 2 (2): 3–9.Google Scholar
  62. 62.
    Drachman DB: Myasthenia gravis. N Engl J Med 1994, 330: 1797–1810.PubMedCrossRefGoogle Scholar
  63. 63.
    Grob D, Arsura EL, Brunner NG, Namba T: The course of myasthenia gravis and therapies affecting outcome. Ann NYAcad Sci 1987, 505: 472–479.CrossRefGoogle Scholar
  64. 64.
    Engel AG: Review of evidence for loss of motor nerve terminal calcium channels in Lambert-Eaton myasthenic syndrome. Ann NY Acad Sci 1991, 635: 246–258.PubMedCrossRefGoogle Scholar
  65. 65.
    O’Neill JH, Murray NM, Newsom-Davis J: The Lambert-Eaton myasthenic syndrome: A review of 50 cases. Brain 1988, 111: 577–596.PubMedCrossRefGoogle Scholar
  66. 66.
    Chalk CH, Murray NM, Newsom-Davis J: Response of the Lambert-Eaton myasthenic syndrome to treatment of associated small cell lung carcinoma. Neurology 1990, 40: 1552–1556.PubMedCrossRefGoogle Scholar
  67. 67.
    Soliven BC, Lange DJ, Penn AS, et al.: Seronegative myasthenia gravis. Neurology 1988, 38:514–517.Google Scholar
  68. 68.
    Lindstrom JM: Pathophysiology of myasthenia gravis: the mechanisms behind the disease. Adv Neuroimmunol 1994, 1 (2): 3–8.Google Scholar
  69. 69.
    Newsom-Davis J: Myasthenia gravis: The Lambert-Eaton myasthenic syndrome and acquired myotonia. In Diagnostic and Therapeutic Approaches to Myasthenia Gravis. Proceedings of the Annual Meeting of the Myasthenia Gravis Foundation of America, Salt Lake City, Utah, April 28, 1995.Google Scholar
  70. 70.
    Section II: Illustrations of selected waveforms. Muscle & Nerve 1987, 10 (8S): G24 - G52.CrossRefGoogle Scholar
  71. 71.
    Mendell J: Neuromuscular junction disorders: A guide to diagnosis and treatment. Adv Neuroimmunol 1994, 1 (2): 9–16.Google Scholar
  72. 72.
    Hohlfeld R, Engel AG, Kunio I, et al.: Polymyositis mediated by T cell lymphocytes that express the gamma delta receptor. N Engl J Med 1991, 324:877–881.Google Scholar
  73. 73.
    Barohn RJ, Amato AA, Sahenk Z, et al.: Inclusion body myositis: explanation for poor response to immunosuppressive therapy. Neurology 1995, 45:1302–1304.Google Scholar
  74. 74.
    Lotz BP, Engel AG, Nishino H, et al.: Inclusion body myositis. Brain 1989, 112:727–742.Google Scholar
  75. 75.
    Dalakas MC: Polymyositis, dermatomyositis, and inclusion-body myositis. N Engl J Med 1991, 325: 1487–1498.PubMedCrossRefGoogle Scholar
  76. 76.
    Cover photo from Adv Neuroimmunol 1995, 2(1).Google Scholar
  77. 77.
    Hohlfeld R, Engel AG, Kunio I, et al.: The immunobiology of muscle. Immunol Today 1994, 15:269–274.Google Scholar
  78. 78.
    Hohlfeld R: New concepts in the immunobiology of inflammatory myopathy. Adv Neuroimmunol 1995, 2 (1): 4–8.Google Scholar
  79. 79.
    Griggs R, Mendell J, Miller R: Inflammatory Myopathy. In Evaluation and Treatment of Myopathy. Philadelphia: FA Davis; 1995.Google Scholar
  80. 80.
    Dalakas MC, Illa I, Dambrosia JM, et al.: A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. N Engl J Med 1993, 329(27):1993–1999.Google Scholar
  81. 81.
    Shaibani A, Harati Y: Idiopathic inflammatory myopathies: polymyositis, dermatomyositis, inclusion body myositis. In Neuro-Immunology for the Clinician. Edited by Rolak LA, Harati Y. Boston: Butterworth-Heinemann; 1997: 301–316.Google Scholar
  82. 82.
    Riminton DS, Chambers ST, Darkin PJ, et al.: Inclusion body myositis presenting solely as dysphagia. Neurology 1993, 43:1241.Google Scholar
  83. 83.
    Dalakas MC, Dambrosia JM, Sekul EA, et al.: Inclusion body myositis: the efficacy of high-dose intravenous immunoglobulin (IVIg) in patients with inclusion body myositis. Neurology 1995, 45(suppl 4):A208.Google Scholar
  84. 84.
    Pruitt JN, Showalter CJ, Engel AG, et al.: Sporadic inclusion body myositis. Counts of different types of abnormal fibers. Ann Neural 1996, 39:139.Google Scholar
  85. 85.
    Mendell JR, Sahenk Z, Gales T, Paul L: Amyloid filaments in inclusion body myositis. Novel findings provide insight into nature of filaments. Arch Neurol 1991, 48: 1229–1234.PubMedCrossRefGoogle Scholar
  86. 86.
    Mikol J, Felten-Papaiconomou A, Ferchal F, et al.: Inclusion-body myositis: clinicopathological studies and isolation of an adenovirus type 2 from muscle biopsy specimen. Ann Neural 1982, 11:576–581.Google Scholar
  87. 87.
    Griggs RC, Mendell JR, Miller RG: Evaluation and Treatment of Myopathies. Philadelphia: FA Davis; 1995: 172.Google Scholar

Copyright information

© Springer Science+Business Media New York 2003

Authors and Affiliations

  • Michael R. Swenson

There are no affiliations available

Personalised recommendations